• Lipocine posted a net loss of $2.6 million, or ($0.32) a share, for Q2 ended June 30, 2026, widening from a $2.2 million loss.
• Revenue fell to $190,099 from $622,849, reflecting royalty revenue from TLANDO sales of $190,000 and no license revenue.
• Unrestricted cash, cash equivalents and marketable investment securities climbed to $23.3 million at June 30, up from $14.9 million at year-end.
• The Phase 3 trial of LPCN 1154 for postpartum depression missed its primary endpoint; Lipocine scheduled an FDA guidance meeting for Q3 2026.
• The company initiated a new placebo-controlled PPD study while continuing to pursue partnerships for Brlizio (LPCN 1154) and TLANDO outside key territories.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-035913), on August 04, 2026, and is solely responsible for the information contained therein.